增资中国看“进博”丨中国答卷：营商环境助力参展商变投资商

Core Insights - Boehringer Ingelheim has been a long-time participant in the China International Import Expo (CIIE), witnessing the transformation of exhibits into commercial products and accelerating health protection for Chinese residents [1] - The CIIE symbolizes global collaboration and market openness, providing a unique platform for multinational companies like Boehringer Ingelheim to connect deeply with local innovation ecosystems [3] - The company has initiated local production plans for its flagship products in China, marking a significant step in its strategic layout and enhancing Shanghai's role as a core supply hub for the Asia-Pacific region [5] Investment and Development Plans - Boehringer Ingelheim plans to invest over 5 billion RMB in research and development in China over the next five years, focusing on areas such as metabolism, inflammation, eye health, and oncology [6] - The company’s "China Key" strategy aims for new products and indications to achieve simultaneous approval in both China and global markets [6] Market Environment - The company appreciates China's ongoing improvements in the business environment and healthcare reforms, which create a more open, fair, and predictable environment for multinational enterprises [6]